Literature DB >> 10438956

Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation.

P Dentelli1, L Del Sorbo, A Rosso, A Molinar, G Garbarino, G Camussi, L Pegoraro, M F Brizzi.   

Abstract

Angiogenesis is a critical process for growth of new capillary blood vessels from preexisting capillaries and postcapillary venules, both in physiological and pathological conditions. Endothelial cell proliferation is a major component of angiogenesis and it is regulated by several growth factors. It has been previously shown that the human hemopoietic growth factor IL-3 (hIL-3), predominantly produced by activated T lymphocytes, stimulates both endothelial cell proliferation and functional activation. In the present study, we report that hIL-3 is able to induce directional migration and tube formation of HUVEC. The in vivo neoangiogenetic effect of hIL-3 was also demonstrated in a murine model in which Matrigel was used for the delivery of the cytokine, suggesting a role of hIL-3 in sustaining neoangiogenesis. Challenge of HUVEC with hIL-3 lead to the synthesis of platelet-activating factor (PAF), which was found to act as secondary mediator for hIL-3-mediated endothelial cell motility but not for endothelial cell proliferation. Consistent with the role of STAT5 proteins in regulating IL-3-mediated mitogenic signals, we herein report that, in hIL-3-stimulated HUVEC, the recruitment of STAT5A and STAT5B, by the beta common (betac) subunit of the IL-3R, was not affected by PAF receptor blockade.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438956

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Gene therapy for radioprotection.

Authors:  W H Everett; D T Curiel
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

2.  Interleukin-19 induces angiogenesis in the absence of hypoxia by direct and indirect immune mechanisms.

Authors:  Farah Kako; Khatuna Gabunia; Mitali Ray; Sheri E Kelemen; Ross N England; Bashar Kako; Rosario G Scalia; Michael V Autieri
Journal:  Am J Physiol Cell Physiol       Date:  2016-04-06       Impact factor: 4.249

3.  CD4 T-cells regulate angiogenesis and myogenesis.

Authors:  Brian J Kwee; Erica Budina; Alexander J Najibi; David J Mooney
Journal:  Biomaterials       Date:  2018-06-06       Impact factor: 12.479

Review 4.  miRNAs as modulators of angiogenesis.

Authors:  Shira Landskroner-Eiger; Isabelle Moneke; William C Sessa
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

5.  Temporal phenotypic features distinguish polarized macrophages in vitro.

Authors:  David W Melton; Linda M McManus; Jonathan A L Gelfond; Paula K Shireman
Journal:  Autoimmunity       Date:  2015-03-31       Impact factor: 2.815

6.  Terminal arteriolar network structure/function and plasma cytokine levels in db/db and ob/ob mouse skeletal muscle.

Authors:  Melissa K Georgi; Jacqueline Vigilance; Anthony M Dewar; Mary D Frame
Journal:  Microcirculation       Date:  2011-04       Impact factor: 2.628

7.  Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis.

Authors:  Xinhai Yang; Dianhua Qiao; Kristy Meyer; Andreas Friedl
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 8.  MicroRNAs in endothelial cell homeostasis and vascular disease.

Authors:  Carlos Fernández-Hernando; Yajaira Suárez
Journal:  Curr Opin Hematol       Date:  2018-05       Impact factor: 3.284

9.  Implanted microvessels progress through distinct neovascularization phenotypes.

Authors:  Sara S Nunes; Kevin A Greer; Chad M Stiening; Helen Y S Chen; Kameha R Kidd; Mark A Schwartz; Chris J Sullivan; Harish Rekapally; James B Hoying
Journal:  Microvasc Res       Date:  2009-10-13       Impact factor: 3.514

Review 10.  MicroRNAs as pharmacological targets in endothelial cell function and dysfunction.

Authors:  Aránzazu Chamorro-Jorganes; Elisa Araldi; Yajaira Suárez
Journal:  Pharmacol Res       Date:  2013-04-18       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.